A doctor holds a pill bottle while consulting with an elderly patient. A stethoscope and prescriptions are visible.

Every FDA-Approved Weight-Loss Medication Compared (2026)

Every FDA-approved weight-loss medication side by side (checked October 6, 2026): how each is taken, who the label covers, main trial results, boxed warnings and dated prices. Never ranked.

By marketing Updated October 7, 2026 Facts checked October 6, 2026

Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.

Key takeaways

  • On 2026-10-06, FDA labels on DailyMed listed 12 medicines and dose forms with a weight indication, from weekly injections to a short-term pill and one over-the-counter capsule.[1]
  • Average weight change in the main placebo-controlled trials ranged from about 5% (Contrave) to about 21% (Zepbound 15 mg), but the trials differ and are not head-to-head.[25]
  • Qsymia and phentermine are Schedule IV controlled substances; Contrave carries a boxed warning about suicidal thoughts; the GLP-1 medicines carry a thyroid C-cell tumor boxed warning.[6]
  • Weight tends to return after stopping: in STEP 4, people switched to placebo regained 6.9% while those who continued lost a further 7.9%.[26]
  • Compounded semaglutide and tirzepatide are not FDA approved, and Ozempic, Rybelsus and Mounjaro are approved for type 2 diabetes, not weight.[35]

In short: As of October 6, 2026, the FDA labels on DailyMed list 12 medicines (counting brands and their dose forms) for weight reduction: four GLP-1-based options taken as weekly injections or daily pills (Wegovy, Wegovy HD, Wegovy tablets, Zepbound), the daily pill Foundayo, daily liraglutide injections (Saxenda and its generics), Qsymia, Contrave, orlistat (Xenical by prescription, Alli over the counter), short-term phentermine and Imcivree for rare genetic or hypothalamic obesity. They differ in how they are taken, who the label covers, side effects, warnings and price. The trial numbers below come from different studies, so this is a side-by-side, not a ranking.

Every status on this page was read from the current FDA label on DailyMed and from Drugs@FDA on October 6, 2026. If you want the deeper story of one medicine, each name links to its own page, and our medications hub explains how the groups fit together. For a two-way look at the best-known pair, see Wegovy vs Zepbound, which includes the one head-to-head trial.

The list at a glance

  • 12medicines and dose forms with an FDA weight indication on DailyMedDailyMed (FDA labels)
  • 7taken by mouth: Wegovy tablets, Foundayo, Qsymia, Contrave, Xenical, Alli and short-term phentermine
  • 1large head-to-head trial among them (SURMOUNT-5, tirzepatide vs semaglutide)Aronne LJ et al., NEJM 2025

Checked on October 6, 2026

How to read this comparison

Each medicine was tested against a placebo in its own trials, with different people, doses and lengths of follow-up. A bigger number in one trial does not prove a medicine works better than another for you. Only head-to-head trials can say that, and few exist. We list medicines alphabetically within each group and never give an overall score.

Using this page well

  1. Check the label groupSome medicines are for adults only, some for teens, one for rare conditions.
  2. Read the trial rowNote the weeks and the placebo number, not just the headline percent.
  3. Look at warningsBoxed warnings and controlled-substance status matter for many people.
  4. Check the dated pricePrices change often; coverage changes what you pay.
  5. Bring questionsYour clinician weighs your history, other medicines and goals.

The labels all describe the same broad group for long-term weight medicines: adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes this as generally a body mass index (BMI) of 30 or more, or 27 or more with a weight-related health problem. You can check your number with our BMI calculator, but only a clinician can decide whether a medicine fits you.

GLP-1 and GIP/GLP-1 medicines

These medicines act on gut-hormone receptors that help regulate appetite and how much people eat. Semaglutide and liraglutide are GLP-1 receptor agonists, tirzepatide acts on both GIP and GLP-1 receptors, and orforglipron is a small-molecule GLP-1 receptor agonist taken as a pill. Our GLP-1 guide explains how they work, and semaglutide vs tirzepatide compares the two best-known molecules.

MedicineHow it is takenWho the label covers (weight)Main weight trial in the label or paperBoxed warningFirst approved for weight
Foundayo (orforglipron)Tablet once daily, with or without foodAdults with obesity, or overweight plus a weight-related conditionLabel Trial 1: -11.1% vs -2.1% with placebo at the highest dose, 72 weeksThyroid C-cell tumor warning (the label notes orforglipron is not active in rats or mice and did not cause rodent tumors)April 1, 2026
Saxenda and generic liraglutideInjection once dailyAdults with obesity or overweight plus a condition; ages 12+ with obesity and body weight over 60 kgLabel: -7.4% vs -3.0%, 56-week trialThyroid C-cell tumors in rodentsDecember 23, 2014 (Saxenda)
Wegovy injection (semaglutide)Injection once weeklyAdults; ages 12+ with obesity. Also heart-risk reduction and a liver (MASH) use in adultsSTEP 1: -14.9% vs -2.4%, 68 weeksThyroid C-cell tumors in rodentsJune 4, 2021
Wegovy HD (semaglutide 7.2 mg)Injection once weekly, for adults who have tolerated 2.4 mg for at least 4 weeksAdults, weight reduction onlyLabel Study 8: -18.8% vs -3.9%, 72 weeksSame as WegovyMarch 19, 2026 (new dose)
Wegovy tablets (oral semaglutide)Tablet once daily, in the morning on an empty stomach with up to 4 oz of water, then a 30-minute waitAdults; also heart-risk reduction in adults with heart diseaseLabel Study 7 (OASIS 4): -13.6% vs -2.4%, 64 weeksSame as WegovyDecember 22, 2025
Zepbound (tirzepatide)Injection once weekly (pens, vials or KwikPen)Adults; also moderate to severe obstructive sleep apnea in adults with obesitySURMOUNT-1: -15.0% to -20.9% by dose vs -3.1%, 72 weeksThyroid C-cell tumors in ratsNovember 8, 2023
Labels and Drugs@FDA checked on 2026-10-06. Trial results are averages from separate placebo-controlled trials; they are not head-to-head comparisons.

Labels for this group warn about pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney injury from dehydration, allergic reactions and a risk of breathing in stomach contents under anesthesia or deep sedation. The labels say not to combine them with other GLP-1 medicines. The most common side effects are digestive: in the Wegovy 2.4 mg trials, nausea affected 44% vs 16% on placebo. In January 2026, the FDA asked makers to remove the suicidal behavior and ideation warning from Saxenda, Wegovy and Zepbound after reviewing 91 trials. Our GLP-1 side effects guide covers what to expect and when to call your clinician.

Liraglutide is now sold under generic labels too. On October 6, 2026, DailyMed listed generic liraglutide injection labels from several companies; the Teva and Cipla labels we read carry the same weight indication as Saxenda. Other liraglutide products, such as Victoza, are for type 2 diabetes.

Other prescription medicines

MedicineHow it is takenWho the label coversMain weight trial in the labelWarnings to knowFirst approved for weight
Contrave (naltrexone and bupropion)Extended-release tablets, built up over 4 weeks to twice dailyAdults with obesity, or overweight plus a condition; not approved for childrenCOR-I: -5.4% vs -1.3%, 56 weeksBoxed warning: suicidal thoughts and behaviors (bupropion); seizure risk; blood pressure and heart rateSeptember 10, 2014
Imcivree (setmelanotide)Injection once dailyAges 4+ with acquired hypothalamic obesity; ages 2+ with Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiency confirmed by genetic testingHypothalamic obesity trial: BMI -15.84% vs +2.55%No boxed warning; skin darkening, mood changes and other warningsNovember 25, 2020
Phentermine (Adipex-P, Lomaira and generics)Tablets or capsules, short termShort-term (a few weeks) add-on for BMI 30+, or 27+ with risk factorsSmall 12-week trial: -8.1 kg vs -1.7 kgControlled substance (Schedule IV); not for people with heart disease or uncontrolled high blood pressureInitial U.S. approval 1959
Qsymia and generic phentermine-topiramateExtended-release capsule once daily in the morningAdults and ages 12+ with obesity; adults with overweight plus a conditionStudy 1: -10.9% vs -1.6% at the top dose, 56 weeksControlled substance (Schedule IV); can harm an unborn baby (pregnancy tests and a safety program); mood and memory effectsJuly 17, 2012
Xenical (orlistat 120 mg)Capsule with each main meal that contains fat, up to three times a dayObesity management with a BMI of 30+, or 27+ with risk factors; also reducing regainPooled 1-year trials: 13.4 lb vs 5.8 lb lostNo boxed warning; oily spotting and urgent bowel movements are common; liver injury is rareApril 23, 1999
Labels on DailyMed and Drugs@FDA checked on 2026-10-06. Phentermine is the only one labeled for short-term use.

Qsymia and phentermine are controlled substances because of phentermine, which is related to amphetamine. A generic version of phentermine-topiramate extended-release capsules (Teva) is listed on DailyMed with the same indication as Qsymia. Contrave contains bupropion, an antidepressant ingredient, which is why it carries its boxed warning. Our appetite suppressants guide covers these older pills in more depth.

The one over-the-counter option

Alli is orlistat at half the prescription strength (60 mg), sold without a prescription since February 7, 2007, for weight loss in overweight adults aged 18 and older together with a reduced-calorie, low-fat diet. In a 16-week U.S. trial of 391 adults, people taking it lost 3.05 kg on average vs 1.90 kg with placebo. It works by blocking some fat from being absorbed, so meals high in fat bring more digestive side effects. It is the only weight-loss medicine with an FDA approval that you can buy off the shelf; supplements are not FDA approved at all, a difference our supplements guide explains.

Trial results side by side, with the caveats

Average weight change in each medicine's main placebo-controlled trial (alphabetical)Values in %
Average weight change in each medicine's main placebo-controlled trial (alphabetical)
ItemMedicinePlacebo
Contrave (COR-I, 56 wk)5.4%1.3%
Foundayo (Trial 1, 72 wk)11.1%2.1%
Qsymia (Study 1, 56 wk)10.9%1.6%
Saxenda (label, 56 wk)7.4%3%
Wegovy (STEP 1, 68 wk)14.9%2.4%
Wegovy HD (Study 8, 72 wk)18.8%3.9%
Wegovy tablets (Study 7, 64 wk)13.6%2.4%
Zepbound 15 mg (SURMOUNT-1, 72 wk)20.9%3.1%

Bars show average percent weight lost. Separate trials with different people, doses and lengths: not head-to-head and not a ranking.

Source: FDA labels on DailyMed (Contrave, Foundayo, Qsymia, Saxenda, Wegovy) and SURMOUNT-1 (NEJM 2022) (checked on October 6, 2026)

Two things stand out when you read the trials carefully. First, people on placebo also lost weight, because everyone got diet and activity counseling, so the gap between the bars matters more than the medicine’s number alone. Second, many people in these trials stopped treatment early; the labels report how many, and results in everyday life are often a little lower. The one large head-to-head trial in this group, SURMOUNT-5, compared tirzepatide with semaglutide; we cover it on Wegovy vs Zepbound.

Stopping matters too. When people switched from semaglutide to placebo in STEP 4 they regained weight (+6.9% vs a further -7.9% on semaglutide), and SURMOUNT-4 showed a similar pattern with tirzepatide (+14.0% on placebo vs -5.5%). Our keeping weight off guide has the habits that help whichever path you take.

Differences people often weigh

  • Weekly, daily or with meals. Wegovy, Wegovy HD and Zepbound are weekly injections; Saxenda and Imcivree are daily injections; Wegovy tablets have a strict empty-stomach morning routine, while the Foundayo label allows it with or without food; orlistat is taken with fat-containing meals.
  • Other approved uses. Wegovy is also approved to lower the risk of heart attack and stroke in adults with heart disease and obesity or overweight, and Zepbound to treat moderate to severe sleep apnea in adults with obesity. These can matter for coverage too.
  • Age. Wegovy injection, Saxenda and Qsymia are labeled for some teens aged 12 and up; Imcivree starts at age 2 or 4 for its rare conditions; the rest are for adults.
  • Pregnancy plans. Several labels say to stop when pregnancy is recognized, Qsymia requires pregnancy testing, and Zepbound and Foundayo labels advise a backup birth control method for a time after starting and after each dose increase, because they can affect birth control pills.
  • Controlled-substance rules. Phentermine and Qsymia are Schedule IV, which can mean extra prescription rules.

Dated self-pay prices

These are the makers’ own self-pay or cash prices for a month, checked on October 6, 2026. They require a prescription, often exclude people with government insurance, and change often. With insurance, what you pay depends on your plan; our insurance guide and cost hub explain coverage, and Wegovy cost goes deeper on one brand.

Maker self-pay prices per month, by strength (USD)
Maker self-pay prices per month, by strength (USD)
ItemLowHigh
Foundayo tablets$149$349
Qsymia (home delivery)$75$75
Wegovy injection pens$199$349
Wegovy HD pens$399$399
Wegovy tablets$149$299
Zepbound KwikPen$299$449

Wegovy pens: $199 intro price for the first two fills of the lowest doses, then $349. Qsymia: $74.99. Contrave: $99 or less through its own pharmacy. Prices change; confirm before you plan.

Source: NovoCare Pharmacy; Lilly Zepbound and Foundayo savings pages; qsymia.com (checked on October 6, 2026)

Medicare Part D cannot cover drugs used only for weight loss by law, but the CMS Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers Wegovy (injection and tablets), Zepbound KwikPen and Foundayo for a $50 copay to people who meet its criteria. No official consumer price was published for Saxenda, generic liraglutide, Xenical, Alli, phentermine or Imcivree on the pages we checked, so we leave them out rather than guess.

Not on this list, and why

  • Ozempic, Rybelsus and Mounjaro. They contain the same ingredients as Wegovy and Zepbound but are approved for type 2 diabetes, not weight management. See Ozempic for weight loss for what that means in practice.
  • Compounded semaglutide and tirzepatide. The FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are sold. Both shortages ended in 2024 and 2025. Read compounded GLP-1s before you consider one.
  • Investigational medicines. CagriSema, retatrutide and others are still in trials or under FDA review and are not approved. Our emerging medications page and CagriSema explainer track them.
  • Withdrawn medicines. Sibutramine (Meridia) was withdrawn in 2010 and lorcaserin (Belviq) in 2020 after safety findings. The FDA still finds sibutramine hidden in some products sold as supplements.

What this comparison cannot tell you

A table cannot weigh your other conditions, the medicines you already take, pregnancy plans, past side effects, needle comfort or what your plan covers. It also cannot replace the basics: every label pairs the medicine with a reduced-calorie diet and more activity, and protein and strength training help protect muscle while you lose weight, as our muscle loss guide explains. If you want a clinician who works with these medicines, find a provider or read about medical weight loss programs. Our 40-methods comparison puts all of these medicines next to diets, activity, programs and surgery.

Related guides

Weight-Loss Medications: what is approved, how they work, what they costWeight-loss medications explained: what is FDA approved for weight and what is not, how each class…GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…Weight-Loss Costs: medications, programs and procedures, with datesWhat weight-loss treatments cost, with dates: GLP-1 self-pay prices, programs, procedures, Medicare and insurance, HSA and…Alternate-Day Fasting vs 16:8 vs 5:2: Fasting Methods ComparedTypes of intermittent fasting compared: 16:8, 5:2 and alternate-day fasting, what a week looks like on…

Tools for this topic

BMI Calculator for Adults (and what BMI cannot tell you)Free BMI calculator for adults with CDC categories, plus what BMI cannot tell you, why waist…

Latest research

How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…Fake and Counterfeit Weight-Loss Drugs: How to Spot ThemCounterfeit Ozempic has reached U.S. pharmacies three times. The FDA alerts, what online test buys found,…

Questions to ask a professional

  • Given my health history and other medicines, which of these groups would we consider, and which would we avoid?
  • Which boxed warnings or controlled-substance rules apply to the options you would suggest?
  • How would we judge whether a medicine is working, and when?
  • What does my insurance cover, and what would I pay each month?
  • What happens if I stop, and how do we plan for maintenance?
  • How should I protect muscle with protein and strength training while I lose weight?

Frequently asked questions

How many weight-loss medications are FDA approved?

On October 6, 2026, DailyMed listed 12 medicines and dose forms with an FDA weight indication: Wegovy injection, Wegovy HD, Wegovy tablets, Zepbound, Foundayo, Saxenda and generic liraglutide, Qsymia and its generic, Contrave, Xenical, Alli (over the counter), short-term phentermine and Imcivree for rare conditions.

Which weight-loss medication is the best?

There is no single best one. Trial results differ, but so do the people studied, the warnings, the way each is taken and the cost. A clinician can weigh these against your health history and goals.

Is there an FDA-approved weight-loss pill?

Yes. Wegovy tablets (approved December 22, 2025) and Foundayo (approved April 1, 2026) are daily GLP-1 pills. Qsymia, Contrave, orlistat and phentermine are also taken by mouth.

Is Ozempic FDA approved for weight loss?

No. Ozempic is approved for type 2 diabetes. Wegovy contains the same ingredient, semaglutide, and is the version approved for weight management.

Are compounded GLP-1s FDA approved?

No. The FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing.

Can I buy a weight-loss medicine without a prescription?

Only Alli (orlistat 60 mg) is FDA approved for sale over the counter. Every other medicine on this page needs a prescription.

References

  1. WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  2. ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  3. FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
  4. SAXENDA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  5. Liraglutide injection (Teva): prescribing information. Teva Pharmaceuticals; DailyMed (NLM), 2026. (accessed October 6, 2026) Drug label
  6. QSYMIA (phentermine and topiramate) extended-release capsules: prescribing information. Vivus, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  7. Phentermine and topiramate extended-release capsules (Teva): prescribing information. Teva Pharmaceuticals; DailyMed (NLM), 2026. (accessed October 6, 2026) Drug label
  8. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets: prescribing information. Nalpropion Pharmaceuticals, via DailyMed, 2025. (accessed October 6, 2026) Drug label
  9. XENICAL (orlistat) capsules: prescribing information. H2-Pharma / CHEPLAPHARM, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  10. ALLI (orlistat 60 mg) capsules: Drug Facts. Haleon, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  11. IMCIVREE (setmelanotide) injection: prescribing information. Rhythm Pharmaceuticals, via DailyMed, 2026. (accessed October 6, 2026) Drug label
  12. Phentermine hydrochloride tablets: prescribing information. Via DailyMed (generic labeler), 2026. (accessed October 6, 2026) Drug label
  13. Drugs@FDA: Foundayo, NDA 220934. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  14. Drugs@FDA: Wegovy, NDA 215256, approval history. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  15. Drugs@FDA: Wegovy tablets, NDA 218316. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  16. Drugs@FDA: Zepbound, NDA 217806. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  17. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2416394 · PMID 40353578 · NCT05822830 (accessed October 6, 2026) Randomized trial
  18. Drugs@FDA: Saxenda, NDA 206321 (original approval 2014-12-23). U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
  19. Drugs@FDA: Qsymia, NDA 022580 (original approval 2012-07-17). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  20. Drugs@FDA: Contrave, NDA 200063 (original approval 2014-09-10). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  21. Drugs@FDA: Xenical, NDA 020766 (original approval 1999-04-23). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  22. Drugs@FDA: Alli, NDA 021887 (original approval 2007-02-07). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  23. Drugs@FDA: Imcivree, NDA 213793 (original approval 2020-11-25). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  24. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
  25. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi:10.1056/NEJMoa2206038 · PMID 35658024 · NCT04184622 (accessed October 7, 2026) Randomized trial
  26. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
  27. Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. doi:10.1001/jama.2023.24945 · PMID 38078870 · NCT04660643 (accessed October 7, 2026) Randomized trial
  28. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. U.S. Food and Drug Administration, 2026. (accessed October 6, 2026) Government page
  29. Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
  30. Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
  31. Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
  32. Qsymia pricing and home delivery. Vivus. (accessed October 6, 2026) Other
  33. Contrave savings and CurAccess pharmacy. Currax Pharmaceuticals. (accessed October 6, 2026) Other
  34. Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
  35. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
  36. Questions and answers about FDA’s initiative against contaminated weight loss products. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  37. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. U.S. Food and Drug Administration, 2020. (accessed October 6, 2026) Government page
  38. BeSafeRx: your source for online pharmacy information. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
  39. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 7, 2026) Government page

Facts checked on October 6, 2026

Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.